MARTINSRIED/MUNICH, Germany, WALTHAM, Mass., and PRINCETON, N.J., March
9 /PRNewswire-FirstCall/ -- GPC Biotech AG (Frankfurt Stock Exchange: GPC;
TecDAX index; Nasdaq: GPCB) today announced that the Company will hold an
analyst and press meeting in Frankfurt, Germany to discuss financial
results for the fiscal year 2006 and to provide a business update.
The meeting, which will be conducted in English, will be held Thursday,
March 15, 2007 at 14:00 CET/9:00 AM ET in Frankfurt.
The meeting will also be accessible via telephone or webcast. The live
webcast, including synchronized slides, will be available on the GPC
Biotech Web site at http://www.gpc-biotech.com. A replay will be available via the
Web site following the live event.
Dial-in numbers for the analyst and press meeting are as follows:
Participants from Europe: 0049 (0)69 9897 2633 or 0044 (0)20 7365 1832
Participants from the U.S.: 1-718-354-1171
Please dial in 10 minutes before the beginning of the meeting.
GPC Biotech AG is a publicly traded biopharmaceutical company focused
on discovering, developing and commercializing new anticancer drugs. GPC
Biotech's lead product candidate - satraplatin - is an oral platinum-based
compound that has shown highly statistically significant results for
progression-free survival in a Phase 3 registrational trial as a
second-line chemotherapy treatment in hormone-refractory prostate cancer.
The U.S. FDA has granted fast track designation to satraplatin for this
indication, and the rolling NDA submission process for this compound has
been completed. GPC Biotech is also developing a monoclonal antibody with a
novel mechanism-of- action against a variety of lymphoid tumors, currently
in Phase 1 clinical development, and has ongoing drug development and
discovery programs that leverage its expertise in kinase inhibitors. GPC
Biotech AG is headquartered in Martinsried/Munich (Germany), and its wholly
owned U.S. subsidiary has sites in Waltham, Massachusetts and Princeton,
New Jersey. For additional information, please visit GPC Biotech's Web site
at http://www.gpc-biotech.com.
This press release contains forward-looking statements, which express
the current beliefs and expectations of the management of GPC Biotech AG.
Such statements are based on current expectations and are subject to risks
and uncertainties, many of which are beyond our control, that could cause
future results, performance or achievements to differ significantly from
the results, performance or achievements expressed or implied by such
forward-looking statements. Actual results could differ materially
depending on a number of factors, and we caution investors not to place
undue reliance on the forward- looking statements contained in this press
release. In particular, additional information relating to the safety,
efficacy or tolerability of satraplatin may be discovered upon further
analysis of data from the SPARC trial or analysis of additional data from
other ongoing clinical trials for satraplatin. Furthermore, even if these
results are confirmed upon full analysis of the trial, we cannot guarantee
that satraplatin will be approved for marketing in a timely manner, if at
all, by regulatory authorities nor that, if marketed, satraplatin will be a
successful commercial product. We direct you to GPC Biotech's Annual Report
on Form 20-F for the fiscal year ended December 31, 2005 and other reports
filed with the U.S. Securities and Exchange Commission for additional
details on the important factors that may affect the future results,
performance and achievements of GPC Biotech. Forward-looking statements
speak only as of the date on which they are made and GPC Biotech does not
undertake any obligation to update these forward- looking statements, even
if new information becomes available in the future.
The scientific information discussed in this press release related to
satraplatin is preliminary and investigative. Satraplatin has not yet been
approved by the FDA in the U.S., the EMEA in Europe or any other regulatory
authority and no conclusions can or should be drawn regarding its safety or
effectiveness. Only the relevant regulatory authorities can determine
whether satraplatin is safe and effective for the use(s) being
investigated.
GPC Biotech AG
Martin Braendle
Director, Investor Relations & Corporate Communications
Phone: +49 (0)89 8565-2693
ir@gpc-biotech.com
In the U.S.: Laurie Doyle
Director, Investor Relations & Corporate Communications
Phone: +1 781 890 9007 X267
usinvestors@gpc-biotech.com
SOURCE GPC Biotech AG
 back to top
Related links:
http://www.gpc-biotech.com
CONTACT:
Martin Braendle, Director, Investor Relations
& Corporate Communications, +49-0-89-8565-2693,
ir@gpc-biotech.com, or in U.S., Laurie Doyle, Director, Investor
Relations & Corporate Communications, +1-781-890-9007 ext. 267,
usinvestors@gpc-biotech.com, both of GPC Biotech AG
|
